Maintenance Notice (10:30 PM January 4 - 8:00 AM January 5, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197 | Notice of Discontinuing the Use of Password-Protected Compressed Files | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 231277-92-2 | 產品號碼: L0360
Lapatinib
×
![]()
×
纯度/分析方法: >98.0%(T)(HPLC)
別名
- N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[(2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl]quinazolin-4-amine
- N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
文件：
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | L0360 |
| 純度/分析方法 | >98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__2__9H__2__6ClFN__4O__4S = 581.06 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Refrigerated (0-10°C) |
| 儲存在惰性氣體下 | Store under inert gas |
| 應避免的情況 | Air Sensitive,Heat Sensitive |
| 包裝和容器 | 1G-Glass Bottle with Plastic Insert （閲覽圖片）, 250MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 231277-92-2 |
| Reaxys-RN | 10502247 |
| PubChem Substance ID | 468592164 |
| MDL編號 | MFCD09264194 |
產品規格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Volumetric Analysis) | min. 98.0 % |
| Melting point | 145.0 to 149.0 °C |
| NMR | confirm to structure |
性質
| 熔點 | 147 °C |
| Maximum Wavelength | 367(MeOH) nm |
GHS
| 危險性說明 | H362 : May cause harm to breast-fed children. H413 : May cause long lasting harmful effects to aquatic life. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P273 : Avoid release to the environment. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
相關法規
| RTECS # | VA0952500 |
運輸資料
| HS編碼* | 2934.99-000 |
Application
Lapatinib: A Dual Kinase Inhibitor of EGFR and HER2
Lapatinib (GW572016) is a 4-anilinoquinazoline dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases. Advanced breast cancer or metastatic breast cancer often overexpress HER2 which is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Lapatinib plus capecitabine [C2878] (a prodrug of 5-FU [F0151]) has shown potent activity in solid tumors, with the most notable in advanced or metastatic breast cancer. (The product is for research purpose only.)
References
- Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases (a review)
- Molecular predictors of response to trastuzumab and lapatinib in breast cancer (a review)
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。